摘要
目的 观察替雷利珠单抗对三维后装腔内放疗治疗的局部晚期宫颈癌患者的影响。方法 2022年1月至2023年8月,纳入山西医科大学附属运城市中心医院收治的120例局部晚期宫颈癌患者,采取随机数字表法将患者分为对照组和联合治疗组,每组各60例。两组患者均接受调强放射治疗、含铂单药同步化疗,对照组采取单纯三维后装腔内放疗,联合治疗组在三维后装腔内放疗基础上加用替雷利珠单抗治疗。比较两组患者的临床疗效、治疗前后肿瘤体积及血清鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)肿瘤标志物水平、T淋巴细胞亚群(CD4^(+)、CD8^(+))指标变化及不良反应情况。结果 联合治疗组患者疾病控制率[91.67%(55/60)]高于对照组[78.33%(47/60)],差异具有统计学意义(χ^(2)=4.183,P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。治疗后,联合治疗组患者肿瘤体积为(21.65±7.23) cm^(3),SCC水平为(2.58±0.42)μg·L^(-1),CEA水平为(1.85±0.52)μg·m L^(-1),各项指标均低于对照组患者[(47.23±5.23) cm^(3),(4.29±0.76)μg·L^(-1),(2.55±0.62)μg·m L^(-1)],差异具有统计学意义(均P<0.05);治疗后,联合治疗组患者CD4^(+)指标为(29.54±3.85)%,高于对照组(27.65±4.23)%,CD8^(+)指标为(28.11±3.33)%,低于对照组(29.65±2.22)%,差异具有统计学意义(均P<0.05)。结论 替雷利珠单抗可提升三维后装腔内放疗治疗的局部晚期宫颈癌患者临床疗效,降低肿瘤标志物水平,治疗不良反应可耐受。
Objective To observe the impact of tislelizumab on patients with locally advanced cervical cancer undergoing three-dimensional brachytherapy.Methods A total of 120 patients with locally advanced cervical cancer admitted to Yuncheng Central Hospital from January 2022 to August 2023 were enrolled in this study.The 120 patients were randomly divided into the control group and combination group,with 60 in each group.All the patients in both groups received intensity-modulated radiotherapy and platinum-based monotherapy concurrent chemotherapy.The patients in the control group received pure three-dimensional brachytherapy while those in the combination group received tislelizumab in addition to the three-dimensional brachytherapy.The clinical efficacy,changes in tumor volume,and serum levels of squamous cell carcinoma antigen(SCC)and carcinoembryonic antigen(CEA)were compared between the two groups.Meanwhile,the changes in T lymphocyte subsets(CD4^(+),CD8^(+))and the occurrence of adverse reactions were also compared.Results The disease control rate in the combination group(91.67%,55/60)was significantly higher than that in the control(78.33%,47/60)(χ^(2)=4.183,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the tumor volume,SCC and CEA were significantly lower in the combination group than in the control((21.65±7.23)cm3 vs(47.23±5.23)cm^(3)),(2.58±0.42)μg·L^(-1) vs(1.85±0.52)μg·mL^(-1)),(1.85±0.52)μg·mL^(-1) vs(4.29±0.76)μg·mL^(-1))(all P<0.05).Furthermore,the CD4+level was remarkably higher in the combination group than in the control((29.54±3.85)%vs(27.65±4.23)%,P<0.05),while the CD8^(+)level in the combined treatment group was lower than that of the control((28.11±3.33)%vs(29.65±2.22)%,P<0.05).Conclusion Tislelizumab can enhance the clinical efficacy of three-dimensional brachytherapy in patients with locally advanced cervical cancer and reduce tumor marker levels.In addition,the treatment-related adverse reactions are tolerable.
作者
吴立丽
李瑞超
Wu Li-li;Li Rui-chao(Department of Radiotherapy,Yuncheng Central Hospital Affiliated to Shanxi Medical University,Yuncheng 044000,China;Department of Oncology,Yuncheng Central Hospital Affiliated to Shanxi Medical University,Yuncheng 044000,China)
出处
《中国药物应用与监测》
CAS
2024年第5期587-591,共5页
Chinese Journal of Drug Application and Monitoring
关键词
局部晚期宫颈癌
替雷利珠单抗
三维后装腔内放疗
临床疗效
肿瘤标志物
不良反应
Locally advanced cervical cancer
Tirellizumab
Three-dimensional post-capsular radiotherapy
Clinical effficacy
Tumor marker
Adverse reaction
